Compare Stocks: VTVT, ASMB, OVID, and SPRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.53 +3.1%	$28.82	$21.80 ▼ $39.71	$479.09M	1.15	375,167 shs	170,489 shs
OVID Ovid Therapeutics	$2.46 +5.1%	$2.65	$1.18 ▼ $3.11	$480.43M	0.22	1.80 million shs	1.41 million shs
SPRY ARS Pharmaceuticals	$4.23 -7.2%	$5.13	$3.98 ▼ $13.15	$420.66M	0.85	1.58 million shs	1.26 million shs
VTVT vTv Therapeutics	$31.18 +3.7%	$32.02	$19.50 ▼ $44.00	$122.81M	0.21	38,674 shs	12,835 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	+4.39%	-22.75%	-14.12%	-7.73%
OVID Ovid Therapeutics	0.00%	+3.36%	-6.46%	-2.38%	+55.70%
SPRY ARS Pharmaceuticals	0.00%	+3.93%	-16.40%	-46.73%	-61.93%
VTVT vTv Therapeutics	0.00%	+2.00%	-2.13%	-6.90%	+41.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.53 +3.1%	$28.82	$21.80 ▼ $39.71	$479.09M	1.15	375,167 shs	170,489 shs
OVID Ovid Therapeutics	$2.46 +5.1%	$2.65	$1.18 ▼ $3.11	$480.43M	0.22	1.80 million shs	1.41 million shs
SPRY ARS Pharmaceuticals	$4.23 -7.2%	$5.13	$3.98 ▼ $13.15	$420.66M	0.85	1.58 million shs	1.26 million shs
VTVT vTv Therapeutics	$31.18 +3.7%	$32.02	$19.50 ▼ $44.00	$122.81M	0.21	38,674 shs	12,835 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	+4.39%	-22.75%	-14.12%	-7.73%
OVID Ovid Therapeutics	0.00%	+3.36%	-6.46%	-2.38%	+55.70%
SPRY ARS Pharmaceuticals	0.00%	+3.93%	-16.40%	-46.73%	-61.93%
VTVT vTv Therapeutics	0.00%	+2.00%	-2.13%	-6.90%	+41.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	101.87% Upside
OVID Ovid Therapeutics	2.92	Moderate Buy	$6.13	148.98% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	491.02% Upside
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	79.07% Upside

Current Analyst Ratings Breakdown

Latest VTVT, ASMB, OVID, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	OVID Ovid Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
10/6/2026	OVID Ovid Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
10/5/2026	OVID Ovid Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/11/2026	OVID Ovid Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
9/8/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/3/2026	OVID Ovid Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$53.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$72.30M	6.63	N/A	N/A	$13.04 per share	1.80
OVID Ovid Therapeutics	$7.25M	66.27	N/A	N/A	$1.00 per share	2.46
SPRY ARS Pharmaceuticals	$84.28M	4.99	N/A	N/A	$1.16 per share	3.65
VTVT vTv Therapeutics	$1.02M	120.44	N/A	N/A	$16.36 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	$1.02	23.07	470.60	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	N/A	-23.64%	-20.52%	11/11/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest VTVT, ASMB, OVID, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	VTVT vTv Therapeutics	-$1.16	N/A	N/A	N/A	$0.33 million	N/A
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	13.99	13.99
OVID Ovid Therapeutics	0.05	12.39	12.39
SPRY ARS Pharmaceuticals	13.72	3.48	3.28
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
OVID Ovid Therapeutics	72.24%
SPRY ARS Pharmaceuticals	68.16%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
OVID Ovid Therapeutics	7.00%
SPRY ARS Pharmaceuticals	33.80%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
OVID Ovid Therapeutics	23	195.30 million	181.63 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable
VTVT vTv Therapeutics	26	3.94 million	3.70 million	Not Optionable

VTVT, ASMB, OVID, and SPRY Headlines

Recent News About These Companies

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

October 10 at 8:54 AM | markets.businessinsider.com

Millennium Management and Israel Englander Reveal 8.7% Stake in vTv Therapeutics

October 9 at 5:53 PM | kalkinemedia.comK

vTv Therapeutics stock jumps on FDA orphan drug status

October 8 at 4:49 PM | uk.finance.yahoo.com

Analysts Conflicted on These Healthcare Names: vTv Therapeutics (VTVT) and CSL (OtherCMXHF)

October 8 at 6:47 AM | theglobeandmail.com

VTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell Disease

October 8 at 6:47 AM | rttnews.com

FDA grants orphan drug status to vTv Therapeutics' sickle cell drug

October 8 at 6:47 AM | streetinsider.com

Contrasting Milestone Pharmaceuticals (NASDAQ:MIST) and vTv Therapeutics (NASDAQ:VTVT)

October 8 at 2:15 AM | americanbankingnews.com

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

October 7, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from Brokerages

October 7, 2026 | americanbankingnews.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from Brokerages

October 7, 2026 | marketbeat.com

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

October 6, 2026 | globenewswire.com

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

October 5, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

October 3, 2026 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Upgraded to Hold at Wall Street Zen

October 3, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average - Here's What Happened

September 23, 2026 | marketbeat.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 15, 2026

September 15, 2026 | biospace.comB

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 15, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 12, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3, 2026 | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VTVT, ASMB, OVID, and SPRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$23.53 +0.71 (+3.11%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$23.49 -0.04 (-0.17%)

As of 10/9/2026 07:30 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Ovid Therapeutics NASDAQ:OVID

$2.46 +0.12 (+5.13%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.46 +0.00 (+0.20%)

As of 10/9/2026 07:49 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

ARS Pharmaceuticals NASDAQ:SPRY

$4.23 -0.33 (-7.24%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.29 +0.06 (+1.39%)

As of 10/9/2026 07:30 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

vTv Therapeutics NASDAQ:VTVT

$31.18 +1.10 (+3.66%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$31.14 -0.04 (-0.11%)

As of 10/9/2026 04:10 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, ASMB, OVID, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, ASMB, OVID, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, ASMB, OVID, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VTVT, ASMB, OVID, and SPRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, ASMB, OVID, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, ASMB, OVID, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, ASMB, OVID, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VTVT, ASMB, OVID, and SPRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools